<DOC>
	<DOC>NCT00930566</DOC>
	<brief_summary>ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson &amp; Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks, and 1 ECP per week during 1 month. Total = 8 ECP after transplantation.</brief_summary>
	<brief_title>Extracorporal Photopheresis Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Patients ≥ 18 years and &lt; or = 65 years with an hematological malignancy indicated for an allogeneic transplantation after reduced intensity conditioning : due to the age : for patients between 55 and 65 years. or for patients between 18 and 55 years of age presenting a risk of increased toxicity for myeloablative conditioning (cardiac, renal or pulmonary pathology) CML and MPS in blastic phase achieving CR, MM stage II or III, relapse after autologous transplant, achieving a response ≥ 30% or on first line if high risk, NHL in 2nd CR, PR after chemotherapy or autologous transplant, chemosensible. CLL in 2nd CR, PR after chemotherapy or autologous transplant, chemosensible. AML in 2nd CR or in first line for high risk criteria, secondary AML. In AML, high risk criteria are defined by : LAM 7, leukocytes&gt;30000/mm3, cytogenetic abnormalities: t(6,9); 11q23, 17p, 11q, 20q, 21q, 5, del(5q), 7/del7q, del 9q and inv 3q, ALL in 2nd CR or in first line for high risk criteria defined by cytogenetic abnormalities: 11q23, t(9,22); t(1,19); t(4,11). MDS patients without prior chemotherapy HLA identical sibling donor Performans status &lt; or = 2 Patients member of a social security company Age &lt; 18 years or &gt; 65 years Pregnant or lactating females Known HIV positivity Active infectious hepatitis, type A, B or C Performance status &gt; 2 according to WHO Left ventricular ejection fraction &lt; 40% and Alveoluscapillary diffusion &lt; 50% Uncontrollable hypertension with medical therapy Creatinine clearance &lt; 60 ml/min Hypersensitivity or allergy to psoralen (methoxsalen) Disease associated with a photosensitivity Hypersensitivity or allergy to both heparin and citrate products Contraindication to Busulfan, Fludarabine, SAT or methotrexate Hypersensitivity to ciclosporine, mycophenolate mofetil or mycophenolic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Extracorporeal Photopheresis</keyword>
</DOC>